Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7890168 | 0.85 | TBXAS1 (0.59) | TBXAS1PKMCYP4F2CYP4A11USP2 | |
| SCHEMBL1792326 | 0.82 | TSHR (0.55) | TBXAS1PKML3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL5659207 | 0.81 | TBXAS1 (0.62) | TBXAS1PKMCYP4F2CYP4A11USP2 | |
| SCHEMBL68340 | 0.81 | PKM (0.60) | TBXAS1PKMCYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL23229267 | 0.81 | TBXAS1 (0.51) | TBXAS1PKMCYP4F2CYP4A11USP2 | |
| SCHEMBL27688208 | 0.80 | TBXAS1 (0.54) | TBXAS1PKMCYP4F2CYP4A11USP2 | |
| SCHEMBL9198638 | 0.80 | TBXAS1 (0.51) | TBXAS1PKMCYP4F2CYP4A11USP2 | |
| SCHEMBL18050464 | 0.79 | CYP4F2 (0.50) | TBXAS1PKMCYP4F2CYP4A11USP2 | |
| SCHEMBL28392981 | 0.79 | TBXAS1 (0.50) | TBXAS1PKMCYP4F2CYP4A11L3MBTL1 | |
| SCHEMBL5661211 | 0.79 | TBXAS1 (0.53) | TBXAS1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | TBXAS1 282/4885PKM 2247/4885CYP4F2 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.